Sanofi anti-allergy drug hydrochloric acid fiefina tablets have been approved in China

Today (February 19), China's State Drug Administration (NMPA) issued drug approval documents to be received information shows that Sanofi's anti-allergy drug hydrochloric acid non-sofina tablets of the three listing applications have been officially approved in China.
According to publicly available information, hydrochloric acid non-sofana tablets are an H1-subject antagonist, and the drug's approved adaptation may be allergic rhinitis and chronic idynamic urticaria.
Screenshot Source: NMPA has at least 4 subtypes of histamines (H1, H2, H3, and H4) in targeted cells in the human cardiovascular system, skin, smooth muscle, and stomach.
histamine H1 subjects are mainly distributed in a variety of cells, such as vascular endothal, channel smooth muscle, and allergic reactions are very closely related.
When the histamine H1 subject is activated, capillaries dilate and permeability increase, and the smooth muscle contraction and gland secretion of the respiratory tract and digestive tract increase, resulting in itching, erythema, runny nose, sneezing, wheezing, itching and a series of allergic symptoms.
Antihistamines targeting histamine H1 receptors can reduce histamine-activated receptors to an inactive state, reduce allergic inflammation, reduce the expression of inflammatory cytokines and cell adhesion molecules, and reduce the trending effect of acidophils, etc., thus exerting biological effects.
present, antihistamines are mainly divided into the first and second generation of two categories, the second generation of antihistamines have better subject specificity and selectivity, the central inhibition rate is low and so on.
hydrochloric acid non-sofinadine (Allegra) is a second-generation H1-subject antagonist developed by Sanofi, an active metabolite of tetranadine in the human body, with good antihistamine effect.
In the U.S., the drug has been approved by the FDA: it can be used not only to alleviate seasonal and perennennia allergic rhinitis-related symptoms in adults and children over 12 years of age, including sneezing, runny nose, tears, itching, red eyes and nasal/tickle/throat itching;
according to Sanofi's official website, hydrochloric acid fissolamine inhibits histamine-induced skin spots and flare reactions.
a single and twice-daily oral dosing, antihistamine action occurs within 1 hour, reaching maximum in 2 to 3 hours and lasting at least 12 hours.
28 days after the drug was given, no tolerance was found.
In a number of randomized, double-blind, placebo-controlled clinical trials, 60 mg of hydrochloric acid and 120 mg of hydrochloric acid were effective in reducing the symptoms of seasonal allergic rhinitis (spring trees and grass or autumn pollen) and perennial allergic rhinitis (animal dander, dust mites and mold), these symptoms include sneezing, runny nose, nose/mouth/throat itching, as well as itchy eyes, tears, redness.
addition, hydrochloric acid is effective in alleviating the symptoms and signs of chronic idlytic urticaria, including itching and rubella counts.
and there was no significant difference in treatment effectiveness among subgroups of age, sex, race, or weight.
Sanofi's anti-allergy drug hydrochloric acid fiefina tablets have been approved in China, available to allergy sufferers with new treatment options! Follow Medicinal Mingkangde on WeChat Public No